Quantcast

Zometa trial could have national significance (access required)

By: Pat Murphy
Published: October 19, 2009

Tags:

A lawsuit against a Swiss pharmaceutical company went to trial last week in Montana, but a verdict in the case could have national significance for hundreds of plaintiffs suing the company in a mass tort. Peggy L. Stevens of Missoula developed severe dental and jaw-related problems after taking Zometa, a bone-strengthening medication manufactured by Novartis. Her attorneys say the company knew patients taking Zometa were vulnerable to a degenerative jaw disorder called osteonecrosis, particularly those patients who undergo invasive dental procedures, like root canals or tooth extractions.
© Copyright 2012 Lawyers USA. All Rights Reserved.


Comments

You must be logged in to post comments.

Sign-up for alerts

NEW FREE WHITE PAPER: E-Discovery

This FREE e-report brought to you by Lawyers USA contains the latest tips for conducting thorough and successful electronic discovery for your trial in 2012. We’ve analyzed the latest court rulings and trends in e-discovery to help you and your clients avoid sanctions and win your case.

Click here to get your free White Paper today!


FEATURED PODCAST

Baby Boomer lawyers and retirement

Nelson Schwartz from The New York Times recently wrote an article titled, "Easing Out the Gray-Haired. Or Not.," spotlighting the fate of the Baby Boomer generation within law firms. Attorney and co-host Bob Ambrogi welcomes Attorney Valerie C. Samuels, a partner in the firm Posternak Blankstein & Lund LLP and co-chair of the Employment Law Group, and Attorney Roy Ginsburg, to take a look at this generation of baby boomers within law firms, retirement, their fate within the firm, options upon retirement and what this means for law firms: big, small and solo.

Click here to listen to the podcast.

Click here to download the podcast.

Click here for the Podcast archive.